# Granules India (GRANULES) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/granules

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹795.4
- Change: +0.12%
- As of: 2026-11-06
- 1D return: +0.12%
- 5D return: -5.28%
- 1M return: -2.41%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

Granules India (₹795.40) exhibits a conflicting technical structure as of 2026-11-06, characterized by short-term weakness against a longer-term bullish backdrop. On the daily chart, the trend is bearish with price trading below the 20-period and 50-period EMAs and SMAs, while the Supertrend remains negative. Daily ADX at 14.95 indicates weak trend conviction, despite an extreme participation anomaly on the same day where volume was 4.0x normal with no clear directional follow-through. Conversely, the monthly trend remains established and bullish (ADX 29.79), with price above all major moving averages and the Supertrend. The stock sits in the upper-middle of its 252-day range (+67.4%) but near the lower end of its 50-day range (+20.9%). A weekly Harami pattern has formed, suggesting potential consolidation or reversal after recent declines. Key resistance lies at ₹796.78 (pivot) and ₹806.09, while immediate support is at ₹791.00. Annualized volatility stands at +32.2%, with a current drawdown of -12.5% from highs.

- Timeframe Conflict: Daily trend is bearish (price below 20/50 EMA/SMA; Supertrend down) while monthly trend remains bullish (price above all indicators; Supertrend up).
- Momentum & Participation: Daily ADX is weak (14.95); however, an extreme volume anomaly (4.0x ratio) occurred on 2026-11-06 without decisive price direction, signaling indecision.
- Price Positioning: Trading at ₹795.40, located in the lower-middle of the 50-day range (+20.9%) but upper-middle of the 252-day range (+67.4%).
- Key Levels: Immediate resistance at ₹796.78 (pivot) and ₹806.09; support at ₹791.00 and ₹782.57.

- Harami
- Doji
- Bullish Engulfing Reversal
- Inside Bar

### News Context

Granules India reported Q2FY27 results after market hours on Monday, November 3, 2026, showing a 39% jump in profit. Despite the profit growth, revenue growth was steady rather than accelerated, and margins softened due to slowing performance in its US formulations business. Following these results, Emkay Global Financial issued a 'Buy' recommendation with a price target of ₹950 on November 3, 2026. The stock also participated in a broader market advance driven by strong corporate earnings and easing crude oil prices.

- Q2FY27 Profit Growth: Reported a 39% increase in profit for the quarter ended September 2026.
- Margin Pressure: Steady revenue growth was offset by margin softening attributed to a slowdown in the US formulations segment.
- Analyst View: Emkay Global Financial assigned a 'Buy' rating and set a price target of ₹950 on November 3, 2026.
- Market Context: Shares reacted positively alongside other pharma peers amid a three-session winning streak for Indian equities.

- [Buy Granules India; target of Rs 950: Emkay Global Financial](https://www.moneycontrol.com/news/business/stocks/buy-granules-india-target-of-rs-950-emkay-global-financial-2-14067421.html)
- [Indian shares set to extend advance on softer oil, steady earnings](https://www.livemint.com/market/stock-market-news/indian-shares-set-to-extend-advance-on-softer-oil-steady-earnings-11793674161810.html)
- [Here are five Pharma and Healthcare stocks that will be reacting to their Q2 results today](https://www.cnbctv18.com/market/granules-india-wockhardt-sparc-krsnaa-diagnostics-akums-drugs-share-price-q2-results-20025420.htm)
- [Granules India shares in focus on posting 39% jump in Q2 profit](https://www.moneycontrol.com/news/business/markets/granules-india-shares-in-focus-on-posting-39-jump-in-q2-profit-14066694.html)
- [Top stocks to watch today: SBI, NSE, ITC, Sun Pharma, IDBI Bank shares in focus on Tuesday, 3 Nov | Full list](https://www.livemint.com/market/stock-market-news/top-stocks-to-watch-today-sbi-nse-itc-sun-pharma-idbi-bank-shares-in-focus-on-tuesday-3-nov-full-list-11793668822019.html)

### What Changed

On November 6, 2026, Granules India filed the transcript of its Q2 and H1 FY27 earnings conference call with the NSE, marking a significant update to its financial and operational profile. The company reported record quarterly revenue of ₹15,600 million (up 20% YoY) and PAT of ₹1,818 million (up 39% YoY), driven by broad-based growth in North America and Europe. A key structural change is the transition to a net cash position of ₹8,280 million following warrant proceeds. However, gross margins compressed to 64.4% due to higher input and logistics costs linked to West Asia conflicts. Regulatory developments include an FDA Form 483 with eleven observations at the Gagillapur facility (none related to data integrity or cross-contamination) and a successful Swiss Medic GMP inspection for Senn Tides’ Zurich site. Strategically, management outlined a shift toward complex generics and first-to-file ANDAs, with five new product launches planned for Q3/Q4 and a projected ₹2,000 crore capex program over three to four years focused on peptide CDMO capacity in Zurich and Vizag. Additionally, KFin Technologies Limited notified the exchange of a corporate office address change effective December 1, 2026.

- {'date': '2026-11-06', 'details': 'Record quarterly revenue of ₹15,600 million (+20% YoY) and PAT of ₹1,818 million (+39% YoY). Transitioned to a net cash position of ₹8,280 million.', 'development': 'Financial Performance & Cash Position'}
- {'date': '2026-11-06', 'details': 'Gross margin compressed to 64.4% due to West Asia conflict-related logistics/input costs. Announced ₹2,000 crore capex plan for peptide CDMO capacity in Zurich and Vizag.', 'development': 'Margin Compression & Strategic Capex'}
- {'date': '2026-11-06', 'details': 'FDA issued Form 483 with 11 observations at Gagillapur (no data integrity issues); Swiss Medic GMP inspection passed for Zurich site. Five new product launches planned for Q3/Q4.', 'development': 'Regulatory & Product Pipeline Updates'}
- {'date': '2026-11-06', 'details': 'Registrar and Share Transfer Agent KFin Technologies Limited changing corporate office address effective December 1, 2026.', 'development': 'Administrative Change'}

- [Granules India Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GRANULES_06112026102337_NSEBSETRANSCRIPT.pdf)
- [Granules India Limited has informed the Exchange about change in Corporate Office Address of Registrar and Share Transfer Agent |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/GRANULES_06112026102749_RTA_ADDRESS_CHANGE.pdf)

### Official Filings

Granules India Limited reported record Q2 FY27 financials, with revenue rising 20% year-over-year to ₹15,600 million and PAT increasing 39% to ₹1,818 million. A significant capital structure shift occurred as the company converted warrants into equity shares worth ₹10,961.25 million, transitioning from a net debt position of ₹1,012 million in Q1 to a net cash balance of ₹8,280 million by quarter-end. Regulatory developments include eleven observations from a USFDA inspection at the Gagillapur facility; management stated these do not involve data integrity or cross-contamination and have no impact on manufacturing. Additionally, two new wholly-owned subsidiaries were incorporated in Brazil and Mexico to support international expansion.

- Q2 FY27 Revenue: ₹15,600 million (+20% YoY); PAT: ₹1,818 million (+39% YoY).
- Capital Structure: Net cash position of ₹8,280 million achieved following warrant conversion of ₹10,961.25 million.
- Regulatory Status: USFDA Form 483 issued for Gagillapur facility with 11 observations; management confirms no data integrity issues and no operational disruption.
- Expansion: Incorporation of new wholly-owned subsidiaries in Brazil and Mexico.

- [Granules India Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GRANULES_06112026102337_NSEBSETRANSCRIPT.pdf)
- [Granules India Limited has informed the Exchange about change in Corporate Office Address of Registrar and Share Transfer Agent |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/GRANULES_06112026102749_RTA_ADDRESS_CHANGE.pdf)
- [Granules India Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/GRANULES_02112026164630_NSEBSEOUTCOME.pdf)
- [Granules India Limited has informed the Exchange regarding a press release dated November 02, 2026, titled "Press Release ". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/GRANULES_02112026165515_NSEBSEPR.pdf)
- [Granules India Limited has informed the Exchange about Presentation |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GRANULES_02112026170430_NSEBSEINVESTORPRESENTATION.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751216_02112026053536_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751217_02112026053541_WEB.xml)
- [Monitoring Agency Report for the quarter ended September 30, 2026 |SUBJECT: Monitoring Agency Report](https://nsearchives.nseindia.com/corporate/GRANULES_02112026182814_NSEBSEMAREPORT.pdf)
- [Granules India Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GRANULES_02112026212432_Audio_Cover_Letter.pdf)
- [Granules India Limited has informed the Exchange regarding a press release dated October 30, 2026, titled "Granules India s Gagillapur facility completes USFDA inspection with eleven observations". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/GRANULES_30102026225107_NSEBSE30102026.pdf)

### Fundamentals

Granules India demonstrates a robust operational expansion in Q2 FY2026-27, with revenue from operations rising sequentially to ₹1,560 crore and net profit increasing to ₹182 crore. This follows a strong annual trajectory where TTM sales reached ₹5,895 crore and TTM net profit grew to ₹714 crore, supported by a TTM compounded profit growth rate of 37%. The balance sheet reflects significant capacity building, with Property, Plant, and Equipment (PPE) expanding to ₹3,403 crore as of September 2026, up from ₹2,612 crore a year prior. Cash generation remains healthy, with Cash from Operating Activity at ₹793 crore for the fiscal year ended March 2026, although the Cash Conversion Cycle lengthened to 256 days due to higher inventory levels.

A notable divergence exists between top-line strength and per-share metrics: while absolute net profit rose, Basic EPS decreased slightly to ₹7.22 in Q2 FY2026-27 from ₹7.26 in Q1, likely reflecting the dilutive impact of increased equity capital (rising to ₹27 crore by Sep 2026). Interest costs remained controlled at ₹21 crore in Q2, down marginally from Q1, despite total borrowings decreasing to ₹1,101 crore by September 2026. The company’s ROCE improved to 16% in March 2026, indicating efficient utilization of expanded assets.

- Q2 FY2026-27 Revenue hit ₹1,560 crore (+20% YoY), with Net Profit at ₹182 crore; however, Basic EPS dipped to ₹7.22/share from ₹7.26 in Q1.
- Balance sheet expansion is evident: PPE grew to ₹3,403 crore (Sep 2026) and Total Assets to ₹8,872 crore, supporting long-term capacity.
- Liquidity strengthened with Cash & Equivalents rising to ₹945 crore (Sep 2026) and Borrowings falling to ₹1,101 crore, while CFO/EBITDA stood at 87% for FY2026.
- Working capital efficiency requires monitoring: Inventory Days increased to 326 days (Mar 2026) and the Cash Conversion Cycle widened to 256 days.

### Bull Case

Granules India presents a conditional upside case anchored by strong recent profitability and divergent technical momentum across timeframes. The company reported a 39% jump in profit for the second quarter (ended September), signaling robust operational execution despite noted margin softening in its US formulations business. This fundamental strength is reflected in a +44.0% one-year return and a +28.5% year-to-date gain, outperforming shorter-term trends where the stock has seen -5.2% over three months and -4.9% over one month.

Technically, the monthly trend remains bullish with an ADX of 29.79 and a positive directional indicator (PLUS_DI: 25.82), suggesting underlying medium-term strength. However, the daily trend is bearish (ADX: 14.95, MINUS_DI: 25.04), indicating near-term volatility and selling pressure. The stock closed at ₹795.4 on November 6, 2026, trading within a narrow range between support at ₹791.0 and resistance at ₹796.78. A constructive interpretation depends on the stock stabilizing above key daily supports while the monthly bullish structure holds, potentially allowing the near-term weakness to resolve into a continuation of the longer-term upward trajectory.

- Q2 Profit Growth: Reported a 39% jump in profit for the September quarter, demonstrating strong earnings momentum despite margin pressures in the US formulations segment.
- Monthly Technical Strength: The monthly trend remains bullish (ADX 29.79, PLUS_DI 25.82), contrasting with the bearish daily trend and supporting a longer-term constructive view.
- Price Action Context: Closed at ₹795.4 on November 6, 2026, with immediate support at ₹791.0 and resistance at ₹796.78; short-term returns are negative (-4.9% over 1 month) but long-term performance is strong (+44.0% over 1 year).
- Monitoring Condition: Watch for stabilization above the ₹791.0 daily support level; a break below this could invalidate the near-term consolidation phase, while holding it may allow the monthly bullish structure to reassert influence.

- [Buy Granules India; target of Rs 950: Emkay Global Financial](https://www.moneycontrol.com/news/business/stocks/buy-granules-india-target-of-rs-950-emkay-global-financial-2-14067421.html)
- [Indian shares set to extend advance on softer oil, steady earnings](https://www.livemint.com/market/stock-market-news/indian-shares-set-to-extend-advance-on-softer-oil-steady-earnings-11793674161810.html)
- [Here are five Pharma and Healthcare stocks that will be reacting to their Q2 results today](https://www.cnbctv18.com/market/granules-india-wockhardt-sparc-krsnaa-diagnostics-akums-drugs-share-price-q2-results-20025420.htm)
- [Granules India shares in focus on posting 39% jump in Q2 profit](https://www.moneycontrol.com/news/business/markets/granules-india-shares-in-focus-on-posting-39-jump-in-q2-profit-14066694.html)
- [Top stocks to watch today: SBI, NSE, ITC, Sun Pharma, IDBI Bank shares in focus on Tuesday, 3 Nov | Full list](https://www.livemint.com/market/stock-market-news/top-stocks-to-watch-today-sbi-nse-itc-sun-pharma-idbi-bank-shares-in-focus-on-tuesday-3-nov-full-list-11793668822019.html)
- [Granules India Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GRANULES_06112026102337_NSEBSETRANSCRIPT.pdf)
- [Granules India Limited has informed the Exchange about change in Corporate Office Address of Registrar and Share Transfer Agent |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/GRANULES_06112026102749_RTA_ADDRESS_CHANGE.pdf)
- [Granules India Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/GRANULES_02112026164630_NSEBSEOUTCOME.pdf)
- [Granules India Limited has informed the Exchange regarding a press release dated November 02, 2026, titled "Press Release ". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/GRANULES_02112026165515_NSEBSEPR.pdf)
- [Granules India Limited has informed the Exchange about Presentation |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GRANULES_02112026170430_NSEBSEINVESTORPRESENTATION.pdf)

### Bear Case

Granules India faces near-term operational headwinds despite strong profit growth, primarily driven by margin softening in its US formulations business during the September quarter. This structural pressure contrasts with the reported 39% jump in Q2 profit, suggesting that top-line stability may not fully offset cost or pricing challenges in key markets. Technically, the stock is trading in a bearish daily trend, with the Supertrend indicator signaling downside momentum and the 20-day moving average slope remaining negative (-6.65). The share price has retreated -4.9% over the last month and is currently -12.5% below its recent peak, indicating sustained selling pressure. While the monthly trend remains bullish, the divergence between short-term technical weakness and longer-term strength highlights elevated volatility (annualized at +32.2%) and a potential risk of further consolidation if support levels fail to hold.

- Margin softening in the US formulations business during Q2 FY27 contrasts with overall profit growth, highlighting segment-specific operational constraints.
- Daily technical indicators are bearish: Supertrend direction is down, and the 20-day EMA slope is negative (-11.24), reflecting immediate downward pressure.
- The stock is in a correction phase, down -4.9% over one month and currently experiencing a -12.5% drawdown from recent highs.
- High annualized volatility (+32.2%) and an ATR of 3.94% suggest significant price fluctuation risk for holders.

- [Buy Granules India; target of Rs 950: Emkay Global Financial](https://www.moneycontrol.com/news/business/stocks/buy-granules-india-target-of-rs-950-emkay-global-financial-2-14067421.html)
- [Indian shares set to extend advance on softer oil, steady earnings](https://www.livemint.com/market/stock-market-news/indian-shares-set-to-extend-advance-on-softer-oil-steady-earnings-11793674161810.html)
- [Here are five Pharma and Healthcare stocks that will be reacting to their Q2 results today](https://www.cnbctv18.com/market/granules-india-wockhardt-sparc-krsnaa-diagnostics-akums-drugs-share-price-q2-results-20025420.htm)
- [Granules India shares in focus on posting 39% jump in Q2 profit](https://www.moneycontrol.com/news/business/markets/granules-india-shares-in-focus-on-posting-39-jump-in-q2-profit-14066694.html)
- [Top stocks to watch today: SBI, NSE, ITC, Sun Pharma, IDBI Bank shares in focus on Tuesday, 3 Nov | Full list](https://www.livemint.com/market/stock-market-news/top-stocks-to-watch-today-sbi-nse-itc-sun-pharma-idbi-bank-shares-in-focus-on-tuesday-3-nov-full-list-11793668822019.html)
- [Granules India Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GRANULES_06112026102337_NSEBSETRANSCRIPT.pdf)
- [Granules India Limited has informed the Exchange about change in Corporate Office Address of Registrar and Share Transfer Agent |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/GRANULES_06112026102749_RTA_ADDRESS_CHANGE.pdf)
- [Granules India Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/GRANULES_02112026164630_NSEBSEOUTCOME.pdf)
- [Granules India Limited has informed the Exchange regarding a press release dated November 02, 2026, titled "Press Release ". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/GRANULES_02112026165515_NSEBSEPR.pdf)
- [Granules India Limited has informed the Exchange about Presentation |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GRANULES_02112026170430_NSEBSEINVESTORPRESENTATION.pdf)

### FAQs

**What were Granules India's key financial results for the second quarter ended September 30, 2026?**

For Q2 FY27, Granules India reported consolidated revenue of ₹15,600 million (up 20% year-over-year) and profit after tax (PAT) of ₹1,818 million (up 39% YoY). EBITDA stood at ₹3,376 million (up 21%), while gross margin compressed to 64.4% due to higher input and logistics costs.

**Has the company's debt position changed recently, and what regulatory updates were noted?**

The company transitioned to a net cash position of ₹8,280 million following warrant proceeds, compared to a net debt of ₹1,012 million in Q1 FY27. Regulatory updates included an FDA Form 483 with eleven observations at the Gagillapur facility (none related to data integrity) and a successful Swiss Medic GMP inspection for the Zurich site.

**How has the stock performed technically over different timeframes as of November 6, 2026?**

As of November 6, 2026, the stock closed at ₹795.40. It is currently in a bearish daily trend but maintains a bullish monthly and weekly trend. The stock has gained +44.0% over the past year but is down -5.2% over the last three months, with a current drawdown of -12.5%.

- [Buy Granules India; target of Rs 950: Emkay Global Financial](https://www.moneycontrol.com/news/business/stocks/buy-granules-india-target-of-rs-950-emkay-global-financial-2-14067421.html)
- [Indian shares set to extend advance on softer oil, steady earnings](https://www.livemint.com/market/stock-market-news/indian-shares-set-to-extend-advance-on-softer-oil-steady-earnings-11793674161810.html)
- [Here are five Pharma and Healthcare stocks that will be reacting to their Q2 results today](https://www.cnbctv18.com/market/granules-india-wockhardt-sparc-krsnaa-diagnostics-akums-drugs-share-price-q2-results-20025420.htm)
- [Granules India shares in focus on posting 39% jump in Q2 profit](https://www.moneycontrol.com/news/business/markets/granules-india-shares-in-focus-on-posting-39-jump-in-q2-profit-14066694.html)
- [Top stocks to watch today: SBI, NSE, ITC, Sun Pharma, IDBI Bank shares in focus on Tuesday, 3 Nov | Full list](https://www.livemint.com/market/stock-market-news/top-stocks-to-watch-today-sbi-nse-itc-sun-pharma-idbi-bank-shares-in-focus-on-tuesday-3-nov-full-list-11793668822019.html)
- [Granules India Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GRANULES_06112026102337_NSEBSETRANSCRIPT.pdf)
- [Granules India Limited has informed the Exchange about change in Corporate Office Address of Registrar and Share Transfer Agent |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/GRANULES_06112026102749_RTA_ADDRESS_CHANGE.pdf)
- [Granules India Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/GRANULES_02112026164630_NSEBSEOUTCOME.pdf)
- [Granules India Limited has informed the Exchange regarding a press release dated November 02, 2026, titled "Press Release ". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/GRANULES_02112026165515_NSEBSEPR.pdf)
- [Granules India Limited has informed the Exchange about Presentation |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GRANULES_02112026170430_NSEBSEINVESTORPRESENTATION.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Downtrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹796.78
- Risk regime: Price Risk Currently Contained

### Support levels
- 791
- 566.75
- 556.46875

### Resistance levels
- 806.0875
- 850.7
- 864.1

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.12% |
| return_10 | +0.08% |
| return_1m | -4.90% |
| return_1y | +44.03% |
| return_20 | -2.41% |
| return_3m | -5.16% |
| return_5 | -5.28% |
| return_6m | +8.07% |
| return_since_start | +33.14% |
| return_ytd | +28.46% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -30.03% |
| annualized_volatility | +32.17% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Granules India Limited Q2 FY2026-27: Revenue up 5.6% sequentially

Granules India reported consolidated revenue from operations of ₹1,560 crore in Q2 FY2026-27, up 5.6% sequentially and 20.3% year on year. Profit before tax rose 1.3% sequentially to ₹243 crore and 38.4% year on year, while expenses increased 7.2% from the previous quarter.

## Revenue and expenses

Revenue from operations rose for a fourth consecutive quarter, from ₹1,388 crore in Q3 FY2025-26 to ₹1,471 crore in Q4 FY2025-26, ₹1,477 crore in Q1 FY2026-27 and ₹1,560 crore in Q2 FY2026-27. The latest sequential increase was ₹83 crore. Expenses reached ₹1,327 crore, up ₹89 crore from Q1 FY2026-27 and 18.5% from Q2 FY2025-26.

## Profit and per-share earnings

Profit before tax was ₹243 crore, compared with ₹240 crore in Q1 FY2026-27 and ₹262 crore in Q4 FY2025-26. Profit for the period was ₹182 crore, versus ₹180 crore in Q1 and ₹131 crore in Q2 FY2025-26. Tax expense was ₹62 crore, up from ₹60 crore in Q1.

Basic earnings per share were ₹7.22, slightly below ₹7.26 in Q1 FY2026-27 and above ₹5.38 in Q2 FY2025-26. Depreciation, depletion and amortisation expense was ₹84 crore. Finance costs were ₹21 crore, broadly unchanged from Q1 and below ₹29 crore in Q2 FY2025-26.

## Balance sheet

At 30 September 2026, total assets were ₹8,872 crore, compared with ₹7,720 crore at 31 March 2026 and ₹6,944 crore at 30 September 2025. Property, plant and equipment stood at ₹3,403 crore, up from ₹3,051 crore and ₹2,612 crore at those respective dates. Cash and cash equivalents were ₹945 crore, compared with ₹880 crore at March 2026 and ₹609 crore at September 2025.

Inventories rose to ₹1,861 crore from ₹1,673 crore at 31 March 2026 and ₹1,488 crore at 30 September 2025. Trade receivables were ₹946 crore, versus ₹909 crore and ₹761 crore at those dates. Current borrowings declined to ₹619 crore from ₹1,041 crore at March 2026 and ₹1,320 crore at September 2025. Equity attributable to owners of the parent increased to ₹6,567 crore from ₹5,085 crore and ₹3,983 crore, respectively.

## Key Takeaway

Granules delivered sustained quarterly revenue growth and strong year-on-year increases in profit, but sequential expenses grew faster than revenue and profit before tax edged up only modestly. The balance sheet also expanded over the year, with higher assets and equity alongside lower current borrowings.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q2
- As of: 2026-09-30
- Promoter holding: +37.39%
- FII holding: +20.25%
- DII holding: +15.33%
- Mutual fund holding: +4.26%
- Retail holding: +12.68%
- Promoter pledged: +0.00%

### Major reported shareholders

- KRISHNA PRASAD CHIGURUPATI — +21.85%
- CHIGURUPATI  UMA  DEVI — +12.51%
- SMALLCAP WORLD FUND, INC — +4.54%
- SBI LIFE INSURANCE CO. LTD — +2.91%
- LIFE INSURANCE CORPORATION OF INDIA — +2.04%
- KOTAK MAHINDRA LIFE INSURANCE COMPANY LTD. — +1.83%
- ADITYA BIRLA SUN LIFE MUTUAL FUND - ADITYA BIRLA S — +1.62%
- TYCHE INVESTMENTS PRIVATE LIMITED — +1.30% (Bodies Corporate)
- 360 ONE PIPE FUND — +1.11%
- BASAVA SANKAR RAO KOLLI — +1.07%

## Official filings

- 2026-11-06 — Generic Announcement: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_06112026102337_NSEBSETRANSCRIPT.pdf)
- 2026-11-06 — Generic Announcement: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_06112026102749_RTA_ADDRESS_CHANGE.pdf)
- 2026-11-02 — Generic Announcement: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_02112026164630_NSEBSEOUTCOME.pdf)
- 2026-11-02 — Press Release: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_02112026165515_NSEBSEPR.pdf)
- 2026-11-02 — Generic Announcement: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_02112026170430_NSEBSEINVESTORPRESENTATION.pdf)
- 2026-11-02 — Financial Results Filing: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751216_02112026053536_WEB.xml)
- 2026-11-02 — Financial Results Filing: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751217_02112026053541_WEB.xml)
- 2026-11-02 — Generic Announcement: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_02112026182814_NSEBSEMAREPORT.pdf)
- 2026-11-02 — Generic Announcement: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_02112026212432_Audio_Cover_Letter.pdf)
- 2026-10-30 — Press Release: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_30102026225107_NSEBSE30102026.pdf)
- 2026-10-26 — Generic Announcement: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_26102026105143_NSEBSEEARNINGSCALL.pdf)
- 2026-10-23 — Board Meeting Notice: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_2296_WebXMLFile_20261023_152702383.xml)
- 2026-10-23 — Generic Announcement: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_2296_WebXMLFile_20261023_152702383.xml)
- 2026-10-23 — Generic Announcement: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_23102026152810_NSEBSEINTIMATIONNEWCOMPANY.pdf)
- 2026-10-23 — Board Meeting Notice: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_23102026153559_NSEBSEINTIMATION.pdf)
- 2026-10-09 — Shareholding Disclosure: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1734932_09102026041953_WEB.xml)
- 2026-10-07 — Press Release: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_07102026124124_NSEBSEPR.pdf)
- 2026-10-06 — Generic Announcement: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_06102026172845_NSEBSETRANSCRIPT.pdf)
- 2026-10-05 — Regulatory Filing: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_10052026123936_53707.zip)
- 2026-10-02 — Generic Announcement: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_02102026202829_NSEBSENEWCOMPANY.pdf)
- 2026-09-29 — Generic Announcement: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_29092026190614_Audiorecording.pdf)
- 2026-09-25 — Generic Announcement: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_2296_WebXMLFile_20260925_101950431.xml)
- 2026-09-25 — Generic Announcement: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_25092026102104_NSEBSE.pdf)
- 2026-09-25 — Regulatory Filing: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_09252026142721_53376.zip)
- 2026-09-25 — Regulatory Filing: Granules India Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GRANULES_09252026162942_53380.zip)

## News and market events

- 2026-11-07 — Economic Times: **More than family business: Drugmakers make costly, long-term strategic shifts as next generation steps into bigger roles** — India's family-run pharmaceutical companies, including Laurus Labs, Granules India, Bharat Biotech, Sun Pharma, and Torrent Pharma, are undergoing costly long-term strategic shifts toward complex generics, biologics, and advanced therapeutics as the next generation assumes larger leadership roles. These successors are committing significant capital to capabilities requiring deeper scientific expertise and longer gestation periods, moving away from traditional low-cost manufacturing models. The success of these transitions remains uncertain, with returns expected over decades rather than quarte — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/more-than-family-business-drugmakers-make-costly-long-term-strategic-shifts-as-next-generation-steps-into-bigger-roles/articleshow/135644313.cms)
- 2026-11-03 — MONEYCONTROL: **Buy Granules India; target of Rs 950: Emkay Global Financial** — Emkay Global Financial has issued a 'Buy' recommendation for Granules India, setting a price target of Rs 950. The note was published on November 3, 2026. — [Source](https://www.moneycontrol.com/news/business/stocks/buy-granules-india-target-of-rs-950-emkay-global-financial-2-14067421.html)
- 2026-11-03 — Mint: **Indian shares set to extend advance on softer oil, steady earnings** — Indian shares are expected to open higher, extending a three-session winning streak driven by strong corporate earnings, easing crude oil prices, and renewed foreign investor inflows. Brent crude traded flat at approximately $105 a barrel following geopolitical developments involving Iran, while specific companies like Marico, Dr. Reddy's, and Granules India reported positive quarterly results. — [Source](https://www.livemint.com/market/stock-market-news/indian-shares-set-to-extend-advance-on-softer-oil-steady-earnings-11793674161810.html)
- 2026-11-03 — CNBC-TV18: **Here are five Pharma and Healthcare stocks that will be reacting to their Q2 results today** — Five pharmaceutical and healthcare stocks—Granules India, Wockhardt, SPARC, Krsnaa Diagnostics, and Akums Drugs—are reacting to their September quarter results reported after market hours on Monday. Granules India reported steady revenue growth but faced margin softening due to slowing US formulations business, while Wockhardt saw a 24% revenue increase driven by biotech operations despite margin contraction. Other companies showed varied performance, with Akums Drugs doubling net profit and Krsnaa Diagnostics increasing revenue by 31.5%, whereas SPARC's subsidiary narrowed its losses. — [Source](https://www.cnbctv18.com/market/granules-india-wockhardt-sparc-krsnaa-diagnostics-akums-drugs-share-price-q2-results-20025420.htm)
- 2026-11-03 — MONEYCONTROL: **Granules India shares in focus on posting 39% jump in Q2 profit** — Granules India's shares are in focus after the company reported a 39% jump in its profit for the second quarter. This financial performance has drawn attention to the pharmaceutical manufacturer's recent results. — [Source](https://www.moneycontrol.com/news/business/markets/granules-india-shares-in-focus-on-posting-39-jump-in-q2-profit-14066694.html)
- 2026-11-03 — Mint: **Top stocks to watch today: SBI, NSE, ITC, Sun Pharma, IDBI Bank shares in focus on Tuesday, 3 Nov | Full list** — Indian equity markets are poised for a gap-up opening following a three-session winning streak, with benchmark indices reaching their highest levels in over five weeks. Several stocks including SBI, NSE, ITC, and IDBI Bank remain in focus due to Q2FY27 earnings releases, corporate developments such as NALCO's interim dividend approval, and operational updates from Sun Pharma and PTC India. — [Source](https://www.livemint.com/market/stock-market-news/top-stocks-to-watch-today-sbi-nse-itc-sun-pharma-idbi-bank-shares-in-focus-on-tuesday-3-nov-full-list-11793668822019.html)
- 2026-11-02 — CNBC-TV18: **Granules India Q2 Results: Net profit jumps 39% on higher revenue, EBITDA margin improves** — Granules India reported a 39.2% year-on-year increase in Q2FY27 net profit to ₹182 crore, driven by a 20.3% rise in revenue to ₹1,560 crore and an improvement in EBITDA margin to 21.6%. The company ended the quarter with a net cash position of ₹828 crore, having shifted from net debt in the previous quarter, while noting persistent input and logistics cost pressures amid West Asia tensions. Management indicated that these cost pressures will continue, but the firm is working with customers to manage them and has concluded a US FDA audit at its Gagillapur facility with observations it believes — [Source](https://www.cnbctv18.com/market/stocks/granules-india-share-price-q2-results-net-profit-jumps-39-on-higher-revenue-ebitda-margin-improves-20025085.htm)
- 2026-11-02 — CNBC-TV18: **Stocks to Watch for November 3: ITC, Marico, CONCOR, Petronet LNG and more** — Investors are focusing on companies reporting September-quarter earnings, including Petronet LNG, Marico, CONCOR, Granules India, PTC India, and GSFC, alongside IDBI Bank amid a nationwide employee strike against its proposed stake sale. Key results show mixed performance, with Petronet LNG and Marico posting profit growth while PTC India and GSFC reported significant declines in net profit. Other notable developments include Lupin receiving US FDA approval for Amifampridine Tablets and Balaji Amines reporting a sharp increase in quarterly profits. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-november-3-itc-marico-concor-petronet-lng-and-more-20025147.htm)
- 2026-11-02 — Times of India: **Granules India Q2 net profit rises 39% | Hyderabad News - The Times of India** — Granules India reported a 39% year-on-year increase in Q2FY27 net profit to ₹182 crore and a 20% rise in revenue to ₹1,560 crore, driven by strong demand in North America which accounted for 72% of sales. The company navigated higher input and logistics costs amid West Asia tensions while continuing its strategic shift toward complex generics and peptide CDMO services. Chairman Dr Krishna Prasad Chigurupati noted that the firm holds ₹828 crore in net cash to fund R&D, manufacturing, and quality initiatives. — [Source](https://timesofindia.indiatimes.com/city/hyderabad/granules-india-q2-net-profit-rises-39/articleshow/135464484.cms)
- 2026-11-02 — The Hindu: **Granules India’s Q2 net up 39% at ₹182 crore** — Granules India reported a 39% year-on-year increase in Q2 net profit to ₹182 crore, driven by 20% revenue growth to ₹1,560 crore despite higher input and logistics costs. Chairman Krishna Prasad Chigurupati noted that cost pressures are expected to persist as the company works with customers to manage them with a lag. Additionally, the company concluded a US FDA audit at its Gagillapur site constructively, with observations deemed addressable through corrective actions. — [Source](https://www.thehindubusinessline.com/companies/granules-indias-q2-net-up-39-at-182-crore/article71656699.ece)
- 2026-11-02 — The Hindu: **Granules India net profit rises 39% to ₹182 cr on higher revenue** — Granules India reported a 39% year-on-year increase in consolidated net profit to ₹181.8 crore and a 20% rise in revenue to ₹1,559.9 crore for the September quarter, driven by higher sales despite cost pressures from West Asia tensions. Chairman Krishna Prasad Chigurupati noted that while input and logistics costs are expected to persist, the company is leveraging its ₹828 crore cash position to invest in research, manufacturing, and quality as it transitions toward complex generics and peptide CDMO. Additionally, management stated that observations from a recent U.S. FDA inspection of its Hyd — [Source](https://www.thehindu.com/business/Industry/granules-india-net-profit-rises-39-to-182-cr-on-higher-revenue/article71656931.ece)
- 2026-11-02 — FREEPRESSJOURNAL.IN: **Granules India Reports Rs 1,560 Crore Revenue In Q2FY27, Net Cash Reaches Rs 828 Crore** — Granules India reported a 39 percent increase in net profit to Rs 181.8 crore and a 20 percent rise in operational revenue to Rs 1,560 crore for the quarter ended September 30, 2026, driven by higher sales despite elevated input and logistics costs from West Asia tensions. The company’s finished dosages segment contributed 73 percent of total revenue, with North America accounting for 72 percent of sales, while the firm closed the quarter with a net cash position of Rs 828 crore compared to previous net debt. Additionally, Granules India filed two potential first-to-file abbreviated new drug a — [Source](https://www.freepressjournal.in/business/granules-india-reports-rs-1560-crore-revenue-in-q2fy27-net-cash-reaches-rs-828-crore)
- 2026-11-02 — The Hindu: **Stocks to watch, Nov 2: Vodafone, NCC, Waaree Renewable, Affle, CDSL and more** — The Competition Commission of India cleared Xavier Niel’s Vega SAS to acquire a 16.2% stake in Vodafone Group Plc, while SEBI penalized CDSL and barred EKI Energy Services executives for regulatory violations. Several companies including NCC Ltd, Waaree Renewable Technologies Ltd, and Granules India Ltd reported operational developments such as order wins and regulatory inspections. — [Source](https://www.thehindubusinessline.com/markets/stocks-to-watch-today-vodafone-ncc-waaree-renewable-affle-cdsl-and-more/article71655128.ece)
- 2026-11-02 — The Hindu: **Q2 Results Today Highlights: Marico, Petronet LNG & Granules Q2 profit surges, ITC, UPL , Wockhardt & Escorts Kubota PAT down, MobiKwik posts profit, Devyani International loss narrows** — Several listed companies reported their Q2FY27 standalone financial results, with Petronet LNG and Marico showing significant profit growth, while Escorts Kubota saw a decline in profit after tax. — [Source](https://www.thehindubusinessline.com/markets/q2-results-today-highlights-itc-marico-upl-upl-petronet-lng-nlc-india-mobikwik-wockhardt-nalco-doms-ind-bosch-escorts-kubota-granules-lloyds-ril-jio-company-results-02-november-2026/article71652562.ece)
- 2026-11-02 — MONEYCONTROL: **Granules India shares in focus after USFDA concludes Hyderabad facility inspection with 11 observations** — The USFDA has concluded an inspection of Granules India's Hyderabad facility, resulting in 11 observations. This development is currently influencing investor focus on the company's shares. — [Source](https://www.moneycontrol.com/news/business/markets/granules-india-shares-in-focus-after-usfda-concludes-hyderabad-facility-inspection-with-11-observations-14065377.html)
- 2026-10-31 — The Hindu: **Finished dosage facility of Granules in Hyderabad gets 11 U.S. FDA observations** — Granules India received 11 observations from the U.S. FDA regarding its Hyderabad finished dosage facility following a CGMP inspection conducted in October 2026. The company stated there is no impact on manufacturing or distribution and will submit a corrective action response within 15 business days. — [Source](https://www.thehindu.com/business/Industry/finished-dosage-facility-of-granules-in-hyderabad-gets-11-us-fda-observations/article71648787.ece)
- 2026-10-31 — CNBC-TV18: **Here's why Granules India shares could see a reaction on Monday** — Granules India reported that the US FDA issued a Form 483 with 11 observations for its Gagillapur, Hyderabad facility after concluding a Good Manufacturing Practice (GMP) inspection. The company stated that none of the observations related to data integrity or cross-contamination and claimed there is no impact on manufacturing or distribution from the site. — [Source](https://www.cnbctv18.com/market/granules-india-share-price-gagilapur-unit-11-usfda-observations-newsbreak-confirmed-impact-conclusion-reaction-20023880.htm)
- 2026-10-30 — CNBC-TV18: **Granules India’s Gagillapur facility gets 11 observations in USFDA inspection** — Granules India Limited reported that its Gagillapur facility received 11 observations from the USFDA following an inspection completed on October 30, 2026, though the company stated there is no impact on manufacturing or distribution. The firm also announced the incorporation of a wholly owned foreign subsidiary, Triton Farmaceutica Do Brasil Ltda, in Brazil to manufacture and distribute pharmaceuticals. — [Source](https://www.cnbctv18.com/business/companies/granules-indias-gagillapur-facility-gets-11-observations-in-usfda-inspection-20023823.htm)
- 2026-10-08 — DECCANCHRONICLE.COM: **AP Govt Attracts Rs.25,000-Cr Investments in Vizag Regional Conference** — Through 31 agreements across high-growth sectors, the investments are expected to create nearly 57,000 jobs — [Source](https://www.deccanchronicle.com/southern-states/andhra-pradesh/ap-govt-attracts-rs25000-cr-investments-in-vizag-regional-conference-1994073)
- 2026-10-08 — MONEYCONTROL: **Andhra Pradesh signs Rs 21,498 crore investment deals, nearly 57,000 jobs in sight** — Andhra Pradesh investments, Andhra Pradesh investment MoUs, Andhra Pradesh Rs 21498 crore investment, CII Partnership Summit 2026, Andhra Pradesh jobs, Visakhapatnam investment summit, Himadri Speciality Chemical Andhra Pradesh, Granules India investment, ReNew Photovoltaics Andhra Pradesh, Andhra Pradesh industrial investment — [Source](https://www.moneycontrol.com/news/business/andhra-pradesh-signs-rs-21-498-crore-investment-deals-nearly-57-000-jobs-in-sight-14047474.html)
- 2026-10-07 — Times of India: **Granules India plans ₹2,000 crore investment to drive growth in complex generics, oncology, and peptide CDMO | Hyderabad News - The Times of India** — Granules India to invest ₹2,000 crore over 3–4 years to expand complex generics, oncology and peptide CDMO, boosting US operations, R&D and global reach. — [Source](https://timesofindia.indiatimes.com/city/hyderabad/granules-india-plans-2000-crore-investment-to-drive-growth-in-complex-generics-oncology-and-peptide-cdmo/articleshow/134744086.cms)
- 2026-10-07 — The Hindu: **Granules eyes first to file status, 180 days exclusivity on generic cancer drug Ruxolitinib in U.S.** — Granules India files Paragraph IV for Ruxolitinib ER tablets, pursuing first-to-file status and 180 days of U.S. generic exclusivity. — [Source](https://www.thehindu.com/business/Industry/granules-eyes-first-to-file-status-180-days-exclusivity-on-generic-cancer-drug-ruxolitinib-in-us/article71554891.ece)
- 2026-09-18 — MONEYCONTROL: **Trade Spotlight: How should you trade Castrol, Ramkrishna Forgings, Sapphire Foods, Jindal Saw, Granules India, and others on September 18?** — Trade Spotlight — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-castrol-ramkrishna-forgings-sapphire-foods-jindal-saw-granules-india-and-others-on-september-18-14032566.html)
- 2026-09-17 — Times of India: **Hyderabad Granules promoter sells 7% stake to raise 1.5k crore** — HYDERABAD: Krishna Prasad Chigurupati, the promoter of Hyderabad-based Granules India, offloaded a nearly 7% (1.72 crore shares) stake in the company . — [Source](https://timesofindia.indiatimes.com/city/hyderabad/hyderabad-granules-promoter-sells-7-stake-to-raise-1-5k-crore/articleshow/134318489.cms)
- 2026-09-17 — The Hindu: **Buzzing stocks for Sept 17: Reliance, Infosys, Krsnaa, Mazagon Dock, Motilal Oswal, Granules,  Fine Organic Chem, Venus Pipes, Highway Infra** — Several Indian companies, including Reliance and Infosys, are making significant moves, from fundraising to new facilities, highlighting a dynamic shift in the corporate landscape — [Source](https://www.thehindubusinessline.com/markets/buzzing-stocks-for-sept-17-reliance-infosys-krsnaa-mazagon-dock-motilal-oswal-granules-fine-organic-chem-venus-pipes-highway-infra/article71475140.ece)

## Business profile

**Strategic vision:** Vertically integrated pharmaceutical company manufacturing APIs, PFIs, and FDs.

### Business segments
- **Active Pharmaceutical Ingredients (API):** Granules India is a manufacturer of first-line defense APIs, including paracetamol, metformin, ibuprofen, guaifenesin, and methocarbamol.
- **Pharmaceutical Formulation Intermediates (PFI):** The company pioneered the commercialization of PFIs for large-volume drugs within the pharmaceutical value chain.
- **Finished Dosages (FD):** Granules India provides multiple finished dosage forms, such as tablets, caplets, and press-fit capsules, offered in bulk, blister packs, and bottles.
- **Oncology Therapeutic Segment:** Granules India has expanded its portfolio by venturing into the Oncology Therapeutic segment, where it develops APIs that are forward-integrated into finished dosages.

### Competitive strengths
- Vertically integrated pharmaceutical manufacturing capabilities.
- Focus on cost-effective product development through R&D.
- Expansion into specialized therapeutic segments like Oncology.
- Development of advanced drug delivery systems.

## Related stocks

- [Acutaas Chemicals Limited (Healthcare)](https://faxioms.com/stocks/acutaas) — +0.30%
- [Blue Jet Healthcare Limited (Healthcare)](https://faxioms.com/stocks/bluejet) — -3.23%
- [Caplin Point Laboratories Limited (Healthcare)](https://faxioms.com/stocks/caplipoint) — -1.64%
- [Cohance Lifesciences Limited (Healthcare)](https://faxioms.com/stocks/cohance) — -3.56%
- [Concord Biotech Limited (Healthcare)](https://faxioms.com/stocks/concordbio) — -6.64%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/granules
Markdown representation: https://faxioms.com/stocks/granules?render=md